Stocks · Healthcare · Biotechnology
Arcus Biosciences, Inc. RCUS
$24.44 -3.13% Close, Oct 2, 2026 · NYSE · Market cap $3.07B
Next earnings report: Oct 27, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Operating margin narrowed to -415.4% from -129.0% a year earlier.
- The diluted share count rose 18.4% in a year.
- Revenue over the last four quarters was $117.0M, down 55.3% from a year earlier, slowing from 67.4% a quarter earlier.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Bottom 10%
- Revenue growth, 3-year CAGRTop 21%
- Revenue growth accelerationBottom 4%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalBottom 18%
- Gross marginTop 14%
- Operating marginBottom 18%
- Accruals (lower is better)Bottom 13%
- Interest coverBottom 26%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldBottom 38%
- Free-cash-flow yieldBottom 29%
- EBITDA / enterprise valueBottom 34%
- Sales / enterprise valueBottom 18%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthTop 13%
- 6-month returnBottom 50%
- 1-year return vs S&P 500Top 19%
- Distance from 52-week highTop 36%
- Trend checklist (0–4)Bottom 38%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersTop 41%
- Consecutive EPS beatsBottom 49%
- Share of analysts rating BuyTop 38%
- Upside to consensus price targetTop 49%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Top 33%
- Maximum drawdown, 3 yearsTop 43%
- Beta vs S&P 500 (lower is better)Bottom 26%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | 67.4% | -55.3% | ↓ |
| Gross margin | 100.0% | 94.0% | ↓ |
| Operating margin | -129.0% | -415.4% | ↓ |
| FCF margin | -130.5% | -406.0% | ↓ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | -55.3% | 67.4% | ↓ | Bottom 10% |
| Gross margin | 94.0% | 100.0% | ↓ | Top 14% |
| Operating margin | -415.4% | -129.0% | ↓ | Bottom 18% |
| Net margin | -386.3% | -116.8% | ↓ | — |
| Free-cash-flow margin | -406.0% | -130.5% | ↓ | — |
| Return on invested capital | -65.8% | — | Bottom 18% | |
| Revenue growth, 3-year CAGR | 30.2% | — | Top 21% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- 2.4%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 53.8%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- +135.3 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- Net cash
- Interest cover (operating income / interest)How many times operating profit covers interest.
- -21.1×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -10.18%
- Shareholder yield
- -10.18%
- Share count change, 1 year
- +18.4%
- Share count change, 3-year CAGR
- +19.9%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 5, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 1
- Beats in the last 8 reports
- 6 of 8
- Average EPS surprise, last 4
- +8.2%
- Average 2-day reaction, last 8
- -0.3%
- Positive 20 days after report
- 6 of 8
Analysts
- Consensus price target
- $40.00
- Target vs current price
- +63.7%
- Analysts with a rating
- 18
- Share rating Buy or Strong Buy
- 83%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 5, 2026 | +19.2% | -3.8% | -0.2% | +3.2% | — |
| May 5, 2026 | -10.9% | +0.0% | -4.6% | -6.1% | +8.4% |
| Feb 25, 2026 | +19.8% | +0.4% | +11.1% | +0.3% | +17.6% |
| Oct 28, 2025 | +4.5% | +6.9% | +9.4% | +24.6% | +19.0% |
| Aug 6, 2025 | +93.4% | -0.6% | +1.3% | +21.9% | +112.5% |
| May 6, 2025 | -11.8% | -9.2% | -1.6% | +12.2% | +2.1% |
| Feb 25, 2025 | +12.0% | +0.8% | +3.3% | -10.2% | -12.7% |
| Nov 6, 2024 | +6.5% | +2.9% | +9.7% | +11.8% | -12.3% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 5, 2026 | -$0.72 | -$0.89 | +19.2% | $41.0M |
| May 5, 2026 | -$1.02 | -$0.92 | -10.9% | $17.0M |
| Feb 25, 2026 | -$0.89 | -$1.11 | +19.8% | $33.0M |
| Oct 28, 2025 | -$1.27 | -$1.33 | +4.5% | $26.0M |
| Aug 6, 2025 | -$0.08 | -$1.14 | +93.4% | $160.0M |
| May 6, 2025 | -$1.14 | -$1.02 | -11.8% | $28.0M |
| Feb 25, 2025 | -$1.03 | -$1.17 | +12.0% | $26.0M |
| Nov 6, 2024 | -$1.00 | -$1.07 | +6.5% | $48.0M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| EV / Sales | 25.96× | — | — | Bottom 18% |
| Free-cash-flow yield | -15.45% | — | — | Bottom 29% |
| Earnings yield | -16.08% | — | — | Bottom 38% |
P/E over the past five years
Range 24.2× – 69.8× since Dec 31, 2021. Each point: price on the filing date divided by trailing-twelve-month EPS known then.
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✗ Price above 200-day average
- ✓ 50-day average above 200-day
- ✓ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 0
- 50-day average slope (20 days)
- -4.8%
- 200-day average slope (20 days)
- +0.8%
- Distance from 50-day average
- -12.1%
- Distance from 200-day average
- -1.3%
- RSI (14)
- 37.2
- Relative volume
- 0.59×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 46.4%
- Volatility vs own 5-year history
- 2th percentile · Low for this stock
- Beta vs S&P 500 (2 years, weekly)
- 1.66
- Correlation with S&P 500
- 0.42
- Current drawdown from 1-year high
- -22.6%
- Maximum drawdown, 3 years
- -66.0%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Nov 23, 2021 | Apr 4, 2025 | -85.8% | 843 days | Not yet recovered |
| Feb 8, 2021 | Jun 22, 2021 | -45.0% | 93 days | 105 days (Nov 18, 2021) |
| Dec 22, 2020 | Dec 31, 2020 | -19.8% | 6 days | 7 days (Jan 12, 2021) |
| Oct 29, 2020 | Nov 6, 2020 | -13.5% | 6 days | 9 days (Nov 19, 2020) |
| Jan 14, 2021 | Jan 27, 2021 | -10.9% | 8 days | 5 days (Feb 3, 2021) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $3.07B
- EPS, diluted (TTM)
- -$3.93
- Revenue (TTM)
- $117.0M
- 52-week range
- $12.89 – $31.74
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $383.0M | $112.0M | $117.0M | $258.0M | $247.0M |
| Gross profit | $383.0M | $112.0M | $117.0M | $258.0M | $237.0M |
| Operating income | $54.0M | -$280.0M | -$340.0M | -$330.0M | -$386.0M |
| Net income | $53.0M | -$267.0M | -$307.0M | -$283.0M | -$353.0M |
| EPS (diluted) | $0.71 | -$3.71 | -$4.15 | -$3.14 | -$3.29 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $48.0M | $26.0M | $28.0M | $160.0M | $26.0M | $33.0M | $17.0M | $41.0M |
| Net income | -$92.0M | -$94.0M | -$112.0M | -$8.0M | -$135.0M | -$98.0M | -$128.0M | -$91.0M |
| EPS (diluted) | -$1.01 | -$1.03 | -$1.14 | -$0.08 | -$1.27 | -$0.92 | -$1.02 | -$0.72 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$256.2M | $438.0M | -$306.0M | -$170.0M | -$482.0M |
| Capital expenditure | -$26.1M | -$6.0M | -$24.0M | -$6.0M | -$2.0M |
| Free cash flow | -$282.2M | $432.0M | -$330.0M | -$176.0M | -$484.0M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $232.3M | $23.0M | $25.0M | $228.0M | $439.0M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $702.0M
- Total assets
- $924.0M
- Total liabilities
- $460.0M
- Total debt
- $114.0M
- Net debt
- -$36.0M
- Shareholders’ equity
- $464.0M
As of Jun 30, 2026 (filed Aug 5, 2026).
Short interest
- Shares sold short
- 13,812,606
- Days to cover
- 7.81
- Change vs previous report
- +5.6%
FINRA short interest, settlement date Sep 15, 2026.